Each issue, The Scientist publishes a list of top-rated papers from a specific subject area, as well as a short review of one or more of the listed papers. We also publish a selection of comments on interesting recent papers from the Faculty of 1000's output. For more information visit www.facultyof1000.com.
A new drug on the market may change this situation. Rapamycin (RAPA), an immunosuppressant, was approved by the Food and Drug Administration three years ago for use in transplant patients. While reading through the literature, Geissler and his colleagues came across some indications that RAPA could alter intracellular signaling pathways in a way that might potentially inhibit angiogenesis, the growth of new blood vessels. If so, it could serve as an anti-cancer agent, as well as an immunosuppressant, by cutting off the blood supply to the growing tumor.
But no evidence existed to suggest that RAPA was actually an ...
